U.S. Gold (USAU) Competitors

Opiant Pharmaceuticals (NASDAQ:OPNT) and U.S. Gold (NASDAQ:USAU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.

Do analysts recommend OPNT or USAU?

U.S. Gold has a consensus price target of $11.00, suggesting a potential upside of 76.00%. Given U.S. Gold's higher probable upside, analysts plainly believe U.S. Gold is more favorable than Opiant Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opiant Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
U.S. Gold	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is OPNT or USAU more profitable?

U.S. Gold has a net margin of 0.00% compared to Opiant Pharmaceuticals' net margin of -147.90%. U.S. Gold's return on equity of -42.74% beat Opiant Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opiant Pharmaceuticals	-147.90%	-97.03%	-59.66%
U.S. Gold	N/A	-42.74%	-32.16%

Which has better earnings & valuation, OPNT or USAU?

Opiant Pharmaceuticals has higher revenue and earnings than U.S. Gold. U.S. Gold is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opiant Pharmaceuticals	$47.78M	0.00	$3.01M	-$6.56	N/A
U.S. Gold	N/A	N/A	-$6.90M	-$0.83	-7.53

Which has more risk & volatility, OPNT or USAU?

Opiant Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, U.S. Gold has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Does the MarketBeat Community prefer OPNT or USAU?

Opiant Pharmaceuticals received 63 more outperform votes than U.S. Gold when rated by MarketBeat users. However, 70.03% of users gave U.S. Gold an outperform vote while only 64.23% of users gave Opiant Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Opiant Pharmaceuticals	Outperform Votes 264 64.23%	Underperform Votes 147 35.77%
U.S. Gold	Outperform Votes 201 70.03%	Underperform Votes 86 29.97%

Do insiders and institutionals have more ownership in OPNT or USAU?

42.4% of Opiant Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.6% of U.S. Gold shares are owned by institutional investors. 25.2% of Opiant Pharmaceuticals shares are owned by company insiders. Comparatively, 9.8% of U.S. Gold shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media prefer OPNT or USAU?

In the previous week, U.S. Gold had 9 more articles in the media than Opiant Pharmaceuticals. MarketBeat recorded 9 mentions for U.S. Gold and 0 mentions for Opiant Pharmaceuticals. U.S. Gold's average media sentiment score of 0.18 beat Opiant Pharmaceuticals' score of 0.00 indicating that U.S. Gold is being referred to more favorably in the news media.

Company	Overall Sentiment
Opiant Pharmaceuticals	Neutral
U.S. Gold	Neutral

Summary

U.S. Gold beats Opiant Pharmaceuticals on 10 of the 16 factors compared between the two stocks.